STOCK TITAN
  1. Home
  2. Financials
  3. DRMAW
  4. EPS (Diluted)

Dermata Therapeutics, Inc. Warrant (DRMAW) EPS by Year

DRMAW

Dermata Therapeutics, Inc. Warrant lost $8.16 per diluted share in fiscal year 2025. The table below carries 6 fiscal years, from 2020 to 2025, and the quarters Dermata Therapeutics, Inc. Warrant has filed alongside them.

FY2025 annual
EPS (Diluted) -$8.16
Source SEC Filings (10-K/10-Q) Latest period Q2 FY2026, ended Jun 30, 2026 Reported Currency USD

Annual figures, oldest first. Point at a bar to read its period.

DRMAW EPS (Diluted) by Fiscal Year

Figures are as reported in USD. Each change compares the year with the year before it, and each column links to the filing it was taken from.

MetricFY2510-KFY2410-KFY2310-KFY2210-KFY2110-KFY2010-K
EPS (Diluted)-$8.16-$80.32-100.9%-$39.99N/AN/AN/A

DRMAW EPS (Diluted) by Quarter

Figures are as reported in USD. Each change compares the quarter with the same quarter a year earlier.

MetricQ2'2610-QQ1'2610-QQ4'2510-QQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-KQ3'2410-QQ2'2410-QQ1'2410-QQ4'2310-KQ3'2310-Q
EPS (Diluted)-$0.74-$0.48-$1.52-107.0%-$1.65-$1.66-$4.47+36.7%$21.86-$20.41-$41.82-$7.06N/AN/A

What diluted earnings per share means

Diluted earnings per share divides net income by the share count the company would have if every option and convertible security were exercised, which is the more conservative of the two per-share figures a filer reports.

More Dermata Therapeutics, Inc. Warrant financials

Frequently Asked Questions

What was Dermata Therapeutics, Inc. Warrant's diluted earnings per share in fiscal year 2025?

Dermata Therapeutics, Inc. Warrant lost $8.16 per diluted share in fiscal year 2025.

What was Dermata Therapeutics, Inc. Warrant's diluted earnings per share in the most recent quarter?

Dermata Therapeutics, Inc. Warrant (DRMAW) reported -$0.74 in diluted earnings per share in Q2 2026.

What does diluted earnings per share mean on a financial statement?

Diluted earnings per share divides net income by the share count the company would have if every option and convertible security were exercised, which is the more conservative of the two per-share figures a filer reports. This page lists what Dermata Therapeutics, Inc. Warrant (DRMAW) reported on that line in every period on record.